Egetis Therapeutics AB (publ) (STO:EGTX)

Market Cap	1.29B
Revenue (ttm)	46.10M
Net Income (ttm)	-343.60M
Shares Out	359.24M
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	227,812
Average Volume	484,112
Open	3.795
Previous Close	3.800
Day's Range	3.620 - 3.795
52-Week Range	3.570 - 9.300
Beta	1.25
RSI	20.65
Earnings Date	Feb 26, 2025

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 40
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EGTX

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.